If someone has told you to “look into clinical trials”, you have probably ended up on ClinicalTrials.gov, looking at a page that reads like a legal document. That is not your fault. The registry is written by researchers, for researchers, and nobody ever rewrote it for the person the study is meant to help.
The good news is that you do not have to read all of it. Six things decide whether a listing is worth bringing to your oncologist, and you can find all six in about two minutes.
1. The status, not the title
Look for the recruitment status near the top. The words matter more than they look like they do:
- Recruiting — the study is taking part in new people now. This is the one you want.
- Not yet recruiting — approved, but not open. Worth noting for later, not for now.
- Enrolling by invitation — only people already identified by the study team can join.
- Active, not recruiting — the study is running but closed to new participants.
- Completed, terminated, withdrawn, suspended — not open, for various reasons.
A study can also be recruiting overall while the site nearest you is not. That distinction is not obvious on the page, and it catches people out constantly.
2. Where it actually is
Scroll to the locations list. It is often long, sorted by country and state, and it is the single biggest reason a promising study turns out to be impractical.
Two things to check. First, how far the nearest site really is, in driving terms rather than straight-line distance. Second, whether that specific site is listed as recruiting, because individual sites open and close independently of the study as a whole.
3. The phase
The phase tells you what question the study is asking, not how good the treatment is. Phase 1 is mostly about safety and dose. Phase 2 asks whether it works against a particular cancer. Phase 3 compares it to the current standard treatment. Phase 4 follows something already approved.
A later phase is not automatically a better option for you. An early-phase study is sometimes the only place a particular drug exists at all.
4. Eligibility, read backwards
This is the part that looks worst and matters most. It comes in two lists: inclusion criteria (things that must be true) and exclusion criteria (things that must not be).
Read the exclusion list first. It is usually shorter, more concrete, and more likely to rule you out quickly, which saves you reading the rest. Look for prior treatments, other health conditions, and organ function requirements.
Then read the inclusion list, and watch for two specific things. Cohorts: many studies split participants into lettered or numbered groups with different requirements, so a criterion may apply only to Cohort 3 and not to you. And line of therapy: a lot of studies require either that you have not been treated yet, or that you have already had a specific treatment. That single requirement decides eligibility more often than anything else.
You will not be able to answer all of it. Nobody can from the outside — some criteria depend on scan measurements and lab values. Unanswered is not the same as ineligible.
5. The NCT number
Every study has an identifier that looks like NCT05498428. Write it down, or copy it.
This is the only unambiguous way to refer to a study. Titles are long, similar to each other, and frequently paraphrased. If you bring one thing to your appointment, bring the NCT number.
6. Who is running it and who to call
Near the bottom there is a contacts section with a study coordinator’s phone number or email, and the sponsor’s name.
You are allowed to call that number. You do not need a referral to ask a question, and coordinators field these calls as part of their job. A short call asking “is your site still enrolling, and does this cohort require prior treatment?” can save you weeks.
What to do with all this
Turn it into one specific question rather than a folder of printouts. “I found NCT05498428, a phase 2 study with a site in Boston, and the group for people who have not started treatment looks like it might apply to me — is it worth pursuing?” is a question your oncologist can answer in the time they have.
That is the whole purpose of reading the listing: not to decide, but to be able to ask well.
Curova does this reading for you and shows which criteria lined up and which did not, so you can skip to the question. But the registry record is always the source of truth, and every study we show links straight back to it.